GRM2 and early-onset autosomal dominant Alzheimer disease: Moreover, mGluR2 antagonists have been considered as major elements of a pharmaceutical composition to treat and prevent acute or chronic neurological disorders including Alzheimer’s disease and mild cognitive impairment (United States Patent 7235547).